<DOC>
	<DOCNO>NCT00372593</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , gemtuzumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving combination chemotherapy together gemtuzumab may kill cancer cell . It yet know whether combination chemotherapy effective without gemtuzumab treat patient newly diagnose acute myeloid leukemia . PURPOSE : This randomized phase III trial study combination chemotherapy gemtuzumab see well work compare combination chemotherapy alone treat young patient newly diagnose acute myeloid leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Gemtuzumab Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare event-free survival ( EFS ) overall survival ( OS ) young patient newly diagnose acute myeloid leukemia ( AML ) treat conventional combination chemotherapy v without gemtuzumab ozogamicin ( GMTZ ) . Secondary - Compare remission induction rate two course therapy patient . - Compare disease-free survival OS patient eligible human leukocyte antigen ( HLA ) -matched family donor ( MFD ) stem cell transplant ( SCT ) virtue risk classification , patient assign MFD SCT MFD available , chemotherapy MFD available . - Determine outcome patient Down syndrome 4 year age old diagnosis treat conventional combination chemotherapy without GMTZ . - Compare EFS OS patient de novo AML treat conventional combination chemotherapy v without GMTZ censor MFD SCT recipient . - Determine prevalence prognostic significance molecular abnormality KIT , CCAAT-enhancer bind protein alpha ( CEBPα ) MLL-Partial tandem duplication ( PTD ) gene patient . - Determine leukemic involvement hematopoietic early progenitor role define response therapy . - Assess ability second-generation flow cytometric assay predict patient high risk relapse period clinical remission . - Examine whether GMTZ significantly improve EFS OS patient higher CD33 concentrations/intensity . - Examine whether GMTZ significantly improve complete remission , EFS , OS cytogenetic risk group ( high- , intermediate- , low-risk ) identify prior Medical Research Council trial . - Utilize fluorescence situ hybridization ( FISH ) analysis identify variant pattern among subgroups patient demonstrate G-banded chromosomal abnormality ( e.g. , inv [ 16 ] /t [ 16 ; 16 ] , [ 8 ; 21 ] , 11q23 abnormality ) determine whether variant pattern account heterogeneity response therapy . - Examine impact complex karyotype ( ≥ 3 , ≥ 4 , ≥ 5 abnormality ) OS EFS intermediate-risk patient high-risk low-risk cytogenetic abnormality exist . OUTLINE : This randomize , multicenter study . Patients stratify accord relapse risk ( high v intermediate v low ) . Patients randomize 1 2 treatment arm . Patients Down syndrome nonrandomly assign arm I ( undergo allogeneic stem cell transplant [ SCT ] ) . - Arm I ( standard therapy ) : - Induction 1 : Patients receive cytarabine IT time diagnosis day 1* . Patients also receive cytarabine IV day 1-10 , daunorubicin hydrochloride IV 6 hour day 1 , 3 , 5 , etoposide IV 4 hour day 1-5 . After 3 week rest , patient ( regardless remission status ) proceed induction 2 . NOTE : *Patients Central Nervous System ( CNS ) disease receive cytarabine IT twice weekly cerebrospinal fluid clear , follow two additional IT treatment . Patients refractory CNS leukemia 6 dose IT treatment remove study . - Induction 2 : Patients receive cytarabine IT day 1 , cytarabine IV day 1-8 , daunorubicin hydrochloride IV 6 hour day 1 , 3 , 5 , etoposide IV 4 hour day 1-5 . After 3 week rest , patient complete remission ( CR ) proceed intensification 1 . Patients refractory disease remove protocol therapy . - Intensification 1 : Patients receive cytarabine IT day 1 , high-dose cytarabine IV 1 hour day 1-5 , etoposide IV 1 hour day 1-5 . After 3 week rest , patient remission proceed intensification 2 , follow intensification 3 . Patients remission proceed allogeneic SCT 2-8 week blood count recover . Patients high-risk disease alternative donor proceed intensification 2 3 , follow allogeneic SCT . Patients remission remove protocol therapy . - Intensification 2 : Patients receive cytarabine IT day 1 , high-dose cytarabine IV 2 hour day 1-4 , mitoxantrone hydrochloride IV 1 hour day 3-6 . After 3 week rest , patient proceed intensification 3 . - Intensification 3 : Patients receive high-dose cytarabine IV 3 hour day 1 , 2 , 8 , 9 asparaginase intramuscularly day 2 9 . - Arm II : - Induction 1 : Patients receive treatment induction 1 arm I . Patients also receive gemtuzumab ozogamicin ( GMTZ ) IV 2 hour day 6 . - Induction 2 : Patients receive treatment induction 2 arm I . - Intensification 1 : Patients receive treatment intensification 1 arm I . - Intensification 2 : Patients receive treatment intensification 2 arm I . Patients also receive GMTZ IV 2 hour day 7 . - Intensification 3 : Patients receive treatment intensification 3 arm I . - Allogeneic SCT ( patient intermediate- high-risk disease ) : - MFD : Patients receive condition regimen comprise busulfan IV 2 hour every 6 hour day -9 -6 cyclophosphamide IV 1 hour day -5 -2 . Patients undergo allogeneic SCT day 0 . Patients receive cyclosporine IV orally twice daily day -1 180 methotrexate IV day 1 , 3 , 6 , 11 . Patients receive graft-vs-host disease ( GVHD ) prophylaxis comprise cyclosporine IV 1-4 hour orally twice daily day -1 180 methotrexate IV day 1 , 3 , 6 , 11 . - Matched alternative donor : Patients receive condition regimen comprise busulfan cyclophosphamide . Patients also receive antithymocyte globulin IV 6-8 hour day -3 -1 . Patients undergo allogeneic SCT receive GVHD prophylaxis . After completion study treatment , patient follow periodically 3 year annually thereafter . PROJECTED ACCRUAL : A total 1,012 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose acute myeloid leukemia ( AML ) Meets customary criterion AML ≥ 20 % bone marrow blast ( WHO classification ) Patients &lt; 20 % bone marrow blast cytopenia myelodysplastic syndrome ( e.g. , chronic myelomonocytic leukemia , refractory anemia ( RA ) , RA excess blast , RA ring sideroblast ) eligible provide 1 follow criterion meet : Karyotypic abnormality characteristic de novo AML ( [ 8 ; 21 ] [ q22 ; q22 ] , inv [ 16 ] [ p13q22 ] , [ 16 ; 16 ] [ p13 ; q22 ] , 11q23 abnormality ) Unequivocal presence megakaryoblasts ( WHO classification ) Isolated myeloid sarcoma ( i.e. , myeloblastoma chloroma ) allow regardless bone marrow result Infants &lt; 1 month age progressive disease* eligible NOTE : *Infants &lt; 1 month age AML may give supportive care clear leukemia regressing ( i.e. , disappearance peripheral blast normalization peripheral blood count ) Patients Down syndrome ≥ 4 year age eligible No juvenile myelomonocytic leukemia No Fanconi 's anemia , Kostmann syndrome , Shwachman syndrome , know bone marrow failure syndrome No promyelocytic leukemia ( M3 ) No secondary treatmentrelated AML Matched family donor criterion ( patient intermediaterisk highrisk disease ) : HLAA , B , C , beta chain ( DRB1 ) , identical 1 antigen allele mismatch molecular high resolution technique All available firstdegree family member ( parent sibling ) must HLA type No syngeneic donor Matched alternative donor criterion ( patient highrisk disease ) : HLAA , B , C , DRB1 , identical 1 antigen allele mismatch donor HLAA , B , DRB1 4 6 antigen match unrelated cord blood donor Mismatched family member donor ≥ 1 haplotype match 5 6 antigen phenotypic match PATIENT CHARACTERISTICS : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior chemotherapy , radiation therapy , antileukemic therapy Topical inhalation steroid condition allow Intrathecal cytarabine give diagnosis allow No prior treatment AML No concurrent peripheral blood stem cell transplantation patient match family donor</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>childhood acute basophilic leukemia</keyword>
	<keyword>childhood acute eosinophilic leukemia</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
</DOC>